Related Experiment Video
Updated: Jan 10, 2026
Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
Published on: November 10, 2023
Subclade B3 and D3 enterovirus D68 among children with severe community-acquired pneumonia in China, 2021 to 2024
Yuanyuan Zhou1, Jiayi Lin2, Xuejie Zhang3
1Infectious Disease Department, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, 201102, China.
Abstract:
Enterovirus D68 (EV-D68) is an emerging pathogen that causes severe respiratory infections in children worldwide and has the potential to re-outbreak. The aim of this study was to assess EV-D68 detection and genetic variability in pediatric patients with community-acquired pneumonia (CAP) during and after the COVID-19 pandemic in China. Respiratory samples, including bronchoalveolar lavage fluid (BALF), were collected from hospitalized children with CAP in Shanghai, Shandong, Fujian, Zhejiang and Jiangsu province between January 1, 2021 and December 31, 2024. Samples were screened for EV-D68 using real-time RT-PCR, and clinical characteristics of positive cases and virus strain sequences were analyzed. Of 2,842 cases, 0.7% (21/2,842) positive with EV-D68. The median age of these patients was 5.0 years (IQR: 3.6-8.0 years), with 42.9% (9/21) presented severe CAP. Of the 21 identified virus strains, 15 belonged to subclade B3 and 6 to subclade D3. In 2024, a total of 14 strains were detected, including 6 from the newly emerged subclade D3. Seven strains, 5 of which were subclade D3, were found in BALF samples from severe CAP patients. One child with severe CAP exhibited subclade D3 EV-D68 viremia. Notable mutations in the VP1 protein included H99D, K168E, and E169K. Our research showed that the EV-D68 continued to spread among children in eastern China before and after the COVID-19 pandemic. From 2021 to 2024, subclades B3 and D3 predominated, with increase detections in 2024 and association with pediatric severe CAP.
More Related Videos
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
12:21A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
Published on: September 28, 2022
Related Concept Videos
01:29Pneumonia II: Pathophysiology
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:30Pneumonia III: Complications and Assessment
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: